Author

Aurelia Tejedor

Observed name: A. Tejedor

Institution: Santa Lucía University General Hospital

Observed institutions: Hospital General Universitario Santa María del Rosell, Santa Lucía University General Hospital

ORCID: 0000-0003-4517-5931

Observed ORCID: 0000-0003-4517-5931

OpenAlex ID: A5018997430

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement

2017 · Ignacio Español, Marta Romera, et al. · Clinical Case Reports · 17

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

2025 · Lucía Pérez-Lamas, Adrián Segura Diaz, et al. · Blood Cancer Journal · 13

Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation

2017 · Felipe de Arriba de la Fuente, Maria Soledad Durán, et al. · Seminars in Hematology · 8

First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone

2009 · I. Español, A. Martínez, et al. · Leukemia Research · 5

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

2024 · Lucía Pérez-Lamas, Adrian Segura Diaz, et al. · Blood · 3

Molecular predictors of anemia response to momelotinib in patients with myelofibrosis: Real-world outcomes from the momgemfin study.

2025 · Adrian Segura Diaz, Lucia Perez Lamas, et al. · Blood

Subcutaneous Bortezomib Plus Melphalan and Prednisone (VMP) in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Patients: Spanish Experience

2015 · F. De Arriba, S. Vidal, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 7

Citation count: 46

H-index: 4

I10-index: 2